Neurolife 5 mg Tablet

Neurolife | 5 mg Tablet
Price: 0.00

Generic: Mirogabalin
Manufactured By: Pharmasia Ltd.

Variant: Tablet 10 mg

Composition

Neurolife 2.5 mg Tablet: Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 2.5 mg.
Neurolife 5 mg Tablet: Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 5 mg.
Neurolife 10 mg Tablet: Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 10 mg.
Neurolife 15 mg Tablet: Each film coated tablet contains Mirogabalin Besylate INN equivalent to Mirogabalin 15 mg.

Pharmacology

Neurolife is considered to exhibit its analgesic effect by reducing Calcium current via binding to the α2δ subunit, which plays an auxiliary role in functions of voltage-gated Calcium channels in the nervous system. Neurolife has a high affinity to and slow dissociation from the α2δ-1 subunits in the dorsal root ganglions hence producing greater therapeutic effects. It also has a low affinity to and fast dissociation from the α2δ-2 subunits in the cerebellum hence producing lesser adverse drug reactions (ADRs).

Indication

Diabetic Peripheral Neuropathy (DPN): Its symptoms include severe pain, hyperalgesia, numbness, impairment of equilibrium and muscle movements, burning pain and pricking pain. Pain is often exacerbated during the night and may cause sleep disorders.

Postherpetic Neuralgia (PHN): Burning pain or pain shooting through the body like electricity persists even after cure of herpes zoster. It is regarded as one of the intractable pains, which cause muscle weakness and paralysis in rare cases.

Peripheral Neuropathic Pain (PNP): Caused by damage or functional abnormality of peripheral nerves due to various causes.

Dose & administration

Route of Administration: By mouth. No food restriction needed when taking Mirogabalin. Normally, the initial dose for adults is 5 mg of Mirogabalin and then the dose is gradually increased by 5 mg at an interval of at least a week to 15 mg. A dose may be adjusted appropriately between 10 mg and 15 mg depending on ages and symptoms, given twice daily. In patients with mild or moderate hepatic impairment, a single 15 mg dose of Mirogabalin did not produce significant ADRs. No dose adjustment needed in mild renal dysfunction. In moderate or severe renal dysfunction, a dose reduction was needed by 50% or 70%. In patients with renal failure, a fixed dose of 7.5 mg once and twice a day reduced Diabetic Peripheral Neuropathy (DPN) and Postherpetic Neuralgia (PHN) with a tolerable level of ADRs.

Contraindication

Neurolife is contraindicated in patients with known hypersensitivity to Mirogabalin or any of its components.

Warning and precaution

Neurolife may impair the ability to drive or operate machinery. Elderly people should be aware of falling and fracture.

Side effects

Common: Dizziness, somnolence, abnormal vision, blurred vision etc.

Rare: Increased AST/ALT, Weight gain, Edema etc.

Withdrawal symptoms: Abrupt discontinuation of treatment with Mirogabalin may cause drug withdrawal symptoms like insomnia, nausea, diarrhea, decreased appetite. Treatment with Mirogabalin should be discontinued gradually.

Use in pregnancy & lactation:

• Pregnancy: For pregnant women and women who may be pregnant, Mirogabalin should be administered only if the expected therapeutic benefits outweigh the possible risks associated with treatment. Animal study has shown that Mirogabalin crossed the placenta.
• Lactation: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits and the benefits of maternal feeding. Animal study has
  shown that Mirogabalin transferred to breast milk.
• Use in children & adolescents: The safety and efficacy of Mirogabalin in children and adolescents have not been established.

Drug interaction:

With medicine: Co-administration of Probenecid 500 mg with Mirogabalin 15 mg increased the Cmax and AUClast of Mirogabalin by 29% and 76%, respectively. Co-administration of Cimetidine 400 mg with Mirogabalin 15 mg increased the Cmax and AUClast of Mirogabalin by 17% and 44%, respectively. Co-administration of Mirogabalin with Ethanol or Lorazepam decreased attention and balance-function more profoundly than monotherapy with Mirogabalin.

With food & others: Fed (high-fat meal) or fasting states in healthy volunteers did not affect bioavailability after taking a single dose of Mirogabalin 15 mg.

Overdose:

Neurolife overdose up to 60 mg/day includes symptoms like euphoric mood, dysarthria, headache, dysphagia, arthritis, joint swelling, and asthenia. In case of a suspected overdose, it is recommended to seek medical attention immediately.

Storage:

Do not store above 25°C, protect from light & moisture. Keep out of the reach of children.

Packs:

• Neurolife 2.5 mg Tablet: Each box contains 20 (2x10’s) tablets in Alu-Alu blister pack.
• Neurolife 5 mg Tablet: Each box contains 30 (3x10’s) tablets in Alu-Alu blister pack.
• Neurolife 10 mg Tablet: Each box contains 30 (3x10’s) tablets in Alu-Alu blister pack.
• Neurolife 15 mg Tablet: Each box contains 20 (2x10’s) tablets in Alu-Alu blister pack.
• Each Alu-Alu blister pack is supplied in light & moisture protected Alu-Alu pouch. Each pouch contains a desiccant bag which is not for consumption.